Pricing Log in Create free account

Greenwich LifeSciences, Inc. (GLSI) vs Keros Therapeutics, Inc. (KROS)

Greenwich LifeSciences, Inc. and Keros Therapeutics, Inc. are both Biotechnology companies. Greenwich LifeSciences, Inc. and Keros Therapeutics, Inc. are of similar size ($224.9M and $220.1M). Across the 10 metrics below, Keros Therapeutics, Inc. leads on 7 and Greenwich LifeSciences, Inc. on 3.

Valuation

Metric GLSI KROS Biotechnology median
P/E n/m n/m 8.42
P/S n/m 6.62 10.01
P/B 71.86 0.84 2.21
Price to free cash flow n/m n/m 21.01
EV/EBITDA n/m 0.38 0.61
EV/Sales n/m (1.14) 9.41
Earnings yield (10.05%) (33.33%) (31.85%)
Free cash flow yield (5.58%) (22.06%) (24.58%)

Profitability

Metric GLSI KROS Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (986.31%) (17.16%) (56.36%)
Return on assets (374.46%) (15.92%) (48.04%)
Return on invested capital 0.00% (1,345.30%) 0.00%

Growth

Metric GLSI KROS Biotechnology median
Revenue growth (TTM) — (84.55%) 6.02%
EPS growth (last fiscal year) (18.18%) 146.00% 30.26%
Revenue growth, 5-year CAGR — 89.45% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GLSI KROS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.54 21.96 4.72
Net debt to EBITDA 0.32 (4.16) 0.96

Dividend

Metric GLSI KROS Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric GLSI KROS Biotechnology median
Market cap 224.87m 220.08m 132.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack